Clinical Pearls in Pediatric Dermatology: Evidence-Based Management Strategies

Pediatric dermatology requires a nuanced approach, as skin conditions in children often present differently than in adults and frequently involve unique physiological considerations. According to the American Academy of Dermatology (AAD), effective management hinges on accurate diagnosis, minimizing systemic exposures, and prioritizing patient-centered care. Clinicians must balance therapeutic potency with the sensitivity of pediatric skin to prevent adverse outcomes.

Distinguishing Atopic Dermatitis from Mimics

Atopic dermatitis (AD) is the most common chronic inflammatory skin condition in children, yet it is frequently misdiagnosed. The National Eczema Association emphasizes that AD typically presents with intense pruritus and a characteristic distribution that shifts with age—often affecting the extensor surfaces in infants and flexural areas in older children.

When a rash fails to respond to standard emollients and topical corticosteroids, clinicians must rule out “atopic mimics.” Common conditions that often masquerade as AD include:

• Seborrheic Dermatitis: Often presents with greasy, yellowish scales, typically on the scalp or in skin folds, without the intense itch characteristic of AD.
• Psoriasis: Pediatric psoriasis often presents with thinner plaques than those seen in adults and may involve the diaper area, a condition known as “napkin psoriasis.”
• Scabies: Persistent pruritus that worsens at night should prompt an investigation for scabies, which often requires a physical examination of the web spaces and skin folds.

Optimizing Topical Corticosteroid Use

Topical corticosteroids remain the gold standard for treating inflammatory dermatoses, but their use in children requires careful selection of potency and vehicle. The Journal of the American Academy of Dermatology notes that the face and intertriginous areas are highly susceptible to skin atrophy and telangiectasia.

To mitigate risks, clinicians should follow the “fingertip unit” rule to ensure appropriate dosing. Furthermore, moving from high-potency agents to lower-potency formulations as inflammation subsides—a process known as “tapering”—is essential to maintain control while reducing the risk of systemic absorption. For chronic maintenance, non-steroidal options such as calcineurin inhibitors or phosphodiesterase-4 inhibitors provide effective alternatives that do not carry the same risk of skin thinning.

Managing Pediatric Acne

Acne in the pediatric population is shifting toward younger age groups, with some patients presenting as early as the prepubertal stage. According to clinical guidelines published in the Journal of Pediatrics, early-onset acne often signals underlying hormonal changes or, rarely, endocrine disorders.

Management strategies for pediatric acne prioritize safety:

• Topical Retinoids: These are foundational for both comedonal and inflammatory acne but require patient education regarding potential irritation and the necessity of sun protection.
• Benzoyl Peroxide: This remains a cornerstone for reducing bacterial load and preventing antibiotic resistance.
• Antibiotic Stewardship: Clinicians are increasingly moving away from long-term oral antibiotics, favoring combination topical therapies to reduce the risk of systemic side effects and the development of resistant bacteria.

Key Considerations for Clinical Practice

| Condition | Primary Diagnostic Clue | Management Priority |
| :— | :— | :— |
| Atopic Dermatitis | Age-specific distribution | Barrier repair and inflammation control |
| Psoriasis | Well-demarcated, silvery scales | Avoiding high-potency steroids on face/folds |
| Pediatric Acne | Early onset (pre-puberty) | Endocrine evaluation if systemic signs exist |

Forward-Looking Trends in Pediatric Skin Care

The future of pediatric dermatology is increasingly focused on targeted biologics for severe, refractory conditions. While systemic treatments were previously reserved for the most extreme cases, the advent of monoclonal antibodies—such as those approved for moderate-to-severe atopic dermatitis—has changed the threshold for intervention. As research continues to expand, the emphasis remains on identifying biomarkers that can predict which children will respond to specific therapies, moving the field toward a more personalized, precision-medicine approach. Clinicians are encouraged to monitor updates from the Society for Pediatric Dermatology to integrate these evolving standards into daily practice.